AQST is trading at $4.25, down 10% as the stock gives back a portion of yesterday’s double-digit post-earnings gains.
- The company reported strong Q1 results with 66% revenue growth and reaffirmed its 2026 financial guidance.
- Management provided key updates regarding the Anaphylm NDA resubmission and the Oaktree refinancing process.
- Today's decline appears to be driven by profit-taking and broader market weakness rather than new negative company-specific news.